Breaking News
World Patient Safety Day 2021: Act Now For Safe And Respectful Childbirth
TIF Takes Active Part In The 71st Session of the WHO Regional Committee for Europe
EdiGene Announces First Patient Enrolment In Phase I Clinical Trial Of Gene-editing Therapy ET-01 For Patients With β-Thalassaemia
TIF Hosting A New Series Of Webinars For TIF Member Associations And T-PAG Members
TIF Position Statement: Demanding Access To Existing And Upcoming Gene Therapies For β-Thalassaemia
TIF Issues Charter of Priorities (CoP) For The Global PKD Patient Community
Mitapivat Granted Priority Review By The FDA For Pyruvate Kinase (PK) Deficiency
TIF Presents The Federation’s Annual Report For 2020
CDC, FDA Authorize Third Dose Of COVID-19 Vaccines For The Immunocompromised In The US
TIF e-Academy: Reimagining Thalassaemia and Sickle Cell Disease Education
English
Ελληνικά
Français
Italiano
Menu
Home
Who we are
TIF History
Vision & Mission
Pillars of Work
Board of Directors
Staff Members
TIF Members
Collaborations
Transparency
Awards & Honours
What we do
Education
Country work
Projects
Haemoglobin Disorders
Thalassaemia
Sickle Cell Disease
Clinical Trial Updates
Positions & Policies
Policy Framework
Position Papers
Official Statements
Publications
TIF Publications
Scientific Literature
Additional Resources
Media Centre
News
Newsletters
Events
Videos
Contact us
Search for
Home
/
What we do
What we do
Back to top button
Close
Search for
